The emerging cardiac therapies market in the U.S. and Western Europe is advancing at double-digit rates, propelled by the growing adoption of minimally invasive procedures by interventional cardiologists, technological advancements, supportive reimbursement policies, and an aging population. As such, cardiac OEMs must invest in product branding and procedure awareness among clinicians to overcome adoption barriers and ensure longevity in this sector, according to the study.
“Partnerships and acquisitions are rampant and necessary for this market,” says Transformational Health Industry Principal Sowmya Rajagopalan. “Strategic partnerships increase the capability of the companies to identify growth opportunities, gain first-mover advantage, and achieve significant product development in a highly consolidated ecosystem.”
Market Analysis of Emerging Cardiac Therapies in the United States and Western Europe, Forecast to 2020, a recent insight from Frost & Sullivan’s Advanced Medical Technology Growth Partnership Service program, explores four key market segments: transcatheter aortic valve implantation (TAVI), transcatheter mitral valve repair (TMVR), endovascular aortic repair (EVAR), and left ventricular assisted device (LVAD). The insight provides revenue forecasts, reimbursement trends, drivers, restraints, and top company profiles.
According to the report, competition will intensify over the next five years as new devices will launch with unique and innovative product and next-generation technology characteristics to capture market share. However, the current emerging cardiac therapy implants market will get commoditized by 2030.
In addition, noteworthy market drivers include:
The TAVI market will reach an estimated value of $3.79 billion by 2020, growing at a CAGR of 16.5% during 2015–2020.
In the US and Europe, there are about 500,000 potential patients eligible for TMVR. The procedure volume is expected to register a 15% to 35% growth rate year-over-year until 2020.
The U.S. drives the LVAD market, which lacks penetration in Europe. The segment will reach an estimated value of $1,829 million by 2020.
The EVAR market will be worth $1.85 billion by 2020. Two major mergers and acquisitions (M&A) have set the pace for additional M&A activities as there are too many small participants fighting for minimal market share.